NEIMETH — Pharma Sector Tailwinds Build as Wave ii Base Forms Near Key Floor

Neimeth International Pharmaceuticals remains one of Nigeria’s most closely watched mid-cap healthcare names, operating at the intersection of rising domestic drug demand and persistent foreign-exchange pressure that has challenged import-dependent manufacturers across the sector. The company’s product portfolio spans ethical pharmaceuticals, consumer health, and veterinary lines, giving it diversified revenue exposure that partially insulates it from single-segment downturns. Nigeria’s healthcare spending trajectory remains structurally positive, underpinned by population growth, expanding insurance penetration under the National Health Insurance Authority framework, and government commitments to local pharmaceutical production under the Renewed Hope Agenda. Neimeth has historically benefited from periods of naira stabilisation, as a more predictable FX environment reduces raw material and active pharmaceutical ingredient costs sourced in hard currency. Recent quarters have seen margin compression across Nigerian pharma names due to elevated energy costs and logistics inflation, but early signs of moderation in diesel prices and improved port throughput at Apapa offer some relief heading into the second half of 2026. The stock’s current price level near 10 represents a meaningful discount to the highs above 14 recorded earlier in the year, which may attract value-oriented domestic institutional interest if earnings visibility improves in the upcoming half-year results. Analysts monitoring the NGX healthcare index have noted that Neimeth’s relatively low free-float and thin liquidity can amplify price moves in both directions, making fundamental re-rating catalysts — such as a strong H1 revenue print or a new product registration — particularly impactful for the share price.

Chart Update — 4H

The 1-hour chart for NEIMETH on the NGX shows price has completed a corrective ABC structure from the highs near 14.8, with wave A bottoming around 8.0 and wave B retracing sharply to 12.1 before wave C extended to close out the broader wave ii correction near the 8.5 support zone. From that low, the structure now favours the early development of a five-wave impulsive sequence higher, with wave (1) and wave (2) of the new bullish leg already tentatively in place around the 10.0–9.1 area. The projected path calls for wave (3) to push toward the 12.0 region, followed by a wave (4) pullback and a final wave (5) extension targeting the 13.5–14.0 area to complete blue wave i. A subsequent wave ii retracement back toward the 8.5 level would then set the stage for a larger degree advance, consistent with the broader bullish channel drawn across the chart. Price must hold above the C-wave low near 8.0 to keep this constructive count valid.